You are here: Industry Insights > AbCellera

News List

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies prnasia
September 28, 2021
AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement...
AbCellera to Build Antibody Manufacturing Facility in Canada contractpharma
June 24, 2021
AbCellera has unveiled plans for the construction of a Good Manufacturing Practices (GMP) manufacturing facility in Vancouver for the production of therapeutic antibodies, which will be the first of its kind in Canada.
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares firstwordpharma
June 11, 2021
AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera
AbCellera Breaks Ground on Global HQ in Vancouver contractpharma
May 06, 2021
380,000 square feet of facilities envisioned as creative tech hub expected to be completed in 2023 and 2024.
AbCellera reports bamlanivimab’s potency against SARS-CoV-2 in study pharmaceutical-technology
April 06, 2021
AbCellera (ABCL) has reported that bamlanivimab (LY-CoV555) demonstrated high potency in neutralising SARS-CoV-2 by uniquely binding both up and down confirmations of the spike receptor-binding domain (RBD) in preclinical study.
AbCellera, Gilead collaborate for new multi-year, multi-target antibody discovery expresspharma
April 02, 2021
AbCellera announced agreements to expand its collaboration with Gilead Sciences including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanised mouse technology, the Trianni Mouse.
AbCellera gets EUA from US FDA for its antibody Bamlanivimab, along with Etesevimab for COVID-19 expresspharma
February 10, 2021
Lilly plans to manufacture more than 250,000 doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a million doses by mid-2021.
US buys additional 650,000 doses of Lilly’s Covid-19 antibody for $812.5m pharmaceutical-technology
December 04, 2020
The US government has entered into a purchase agreement worth $812.5m to procure 650,000 additional doses of Eli Lilly and Company’s neutralising antibody bamlanivimab (LY-CoV555) 700mg.
AbCellera antibody gets US FDA EUA as monotherapy for COVID-19 treatment expresspharma
November 11, 2020
AbCellera’s partner, Eli Lilly and Company, will supply the US government with 300,000 doses of bamlanivimab for allocation to high-risk patients.
AbCellera acquires OrthoMab bispecific platform from Dualogics pharmaceutical-business-review
August 25, 2020
AbCellera announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics).

Previous page 1 2 Next page